Please ensure Javascript is enabled for purposes of website accessibility

How Keytruda's Latest Approval in China Boosts Merck

By Kody Kester – Sep 11, 2021 at 9:18AM

Key Points

  • Keytruda could realistically generate $1 billion in annual sales in China from its esophageal cancer indications.
  • The drug continues to receive regulatory approvals for additional indications on a somewhat regular basis.
  • Although oncology is an important part of Merck's business, its vaccines and animal health segments are collectively almost as important.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Keytruda received its second regulatory approval in China for the treatment of esophageal cancer.

Earlier this month, China's National Medical Products Administration (NMPA) announced the approval of Merck's (MRK 0.64%) Keytruda, in combination with platinum- and fluoropyrimidine-based chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic carcinoma of the esophagus or gastroesophageal junction (GEJ).

Overall, this approval marks Keytruda's eighth indication across five different cancers in China. The regulatory approval comes 15 months after the drug was initially approved as a second-line monotherapy for the treatment of patients with another form of esophageal cancer.

Let's examine the burden of esophageal cancer in China, the efficacy of Keytruda in treating locally advanced unresectable or metastatic esophageal or GEJ carcinoma, and the amount of additional revenue that this label expansion could create for Keytruda.

A doctor performs a physical exam on a senior patient.

Image source: Getty Images.

Keytruda proved itself once again

Before going over the data of the Keytruda-and-chemotherapy pairing for patients with locally advanced unresectable or metastatic carcinoma of the esophagus or GEJ, it would be helpful to first explain the terms and the prevalence of this condition within China.

In simpler terms, "locally advanced and unresectable esophageal carcinoma" means that the cancer is more advanced than early-stage cancer, and that tumors are inoperable or can't be removed by surgery. It also means that the cancer has spread to nearby structures of the body like lymph nodes, but it hasn't spread to more distant parts of the body or metastasized.

"Metastatic carcinoma of the esophagus" means that the cancer has spread from its origin in the esophagus (the tube-like structure that extends from the throat to the stomach) to other parts of the body, such as the lungs or brain.

The common symptoms of esophageal cancer, which present more frequently in later stages, include coughing, hoarseness, and difficulty or pain with swallowing. Despite the progress made in treating esophageal cancer in recent years, the five-year survival rate in China remains quite low, at just 39%.

Merck notes that in China, esophageal cancer is "the fifth most commonly diagnosed cancer and the fourth leading cause of death from cancer." Over 324,000 cases of esophageal cancer were diagnosed in the country last year, and 301,000 deaths resulted from the disease during that time.

Fortunately, Merck's Keytruda may be able to help reduce deaths from esophageal cancer. In combination with standard chemotherapy, the drug was found to reduce the risk of death in patients with locally advanced and unresectable esophageal carcinoma or metastatic carcinoma of the esophagus by 27% compared to chemotherapy alone.

Keytruda and chemotherapy also helped patients to live without any progression or worsening of the disease -- referred to as progression-free survival (PFS) -- for longer than just chemotherapy.

The PFS period with the Keytruda-and-chemotherapy combo was 6.3 months, which was superior to the 5.8 months for chemotherapy alone. For better context, it's worth noting that even on the low end of the PFS spectrum in those receiving Keytruda and chemotherapy, patients went 6.2 months without a progression of their symptoms. This is better than the maximum PFS period of 6 months that patients receiving only chemotherapy experienced during the clinical trial.

Given Keytruda's efficacy and the prevalence of esophageal cancer in China, it's understandable why the NMPA approved the drug for another esophageal cancer indication. This is a major win for esophageal cancer patients living in China.

Access to yet another sizable market

But can the approval also be a boon to Merck's shareholders?

Let's assume the esophageal cancer market in China is about the number of patients who were diagnosed with the disease last year: 324,000. Of course, there are hundreds of thousands (at least) of other patients diagnosed before last year who are still alive and potentially in need of a new, more effective treatment. But to be conservative, I'll stick with 324,000 esophageal cancer patients.

Since the latest esophageal cancer indication for Keytruda was as a first-line treatment, I believe that the drug could snag 15% of the esophageal cancer market with this indication. This would mean nearly 49,000 patients in China.

While Keytruda's annual price in China was recently about $80,000, I'll trim this figure considerably, to an annual price of just $15,000. This is because it's inevitable that in a market as large as China, Keytruda will eventually face more intense competition from Chinese biotech firms on oncology-drug pricing across indications such as esophageal cancer. For instance, Shanghai Junshi Biosciences' oncology drug for melanoma (a form of skin cancer), Tuoyi, only cost $27,000 annually when it was launched in December 2018.

With all of this in mind, I believe that the additional esophageal cancer indication for Keytruda will mean an extra $700 million in annual revenue for the company, whose 2020 sales totaled $48 billion.

More than just a leader in oncology

Pharma stock Merck continues to rack up approvals for Keytruda in markets scattered throughout the world.

Here in the U.S., Keytruda, in combination with Merck and Eisai's (ESALY 2.50%) Lenvima, was approved just last month by the U.S. Food and Drug Administration (FDA) to treat patients with advanced renal cell carcinoma.

While Merck's oncology segment and its first-half revenue this year of $8.86 billion accounted for a major part of the company's $22.02 billion in total revenue, Merck's vaccine and animal health segments were almost equally as important in how the company generated revenue.

Similar to the oncology segment, the vaccine and animal health segments both grew their first-half revenue by double digits year over year. And the two segments produced $6.79 billion in combined first-half revenue this year.

Merck's quality collection of businesses should provide earnings stability for the company in the years ahead. That's a key reason that Merck is one of the largest healthcare holdings in my portfolio.

Kody Kester owns shares of Merck & Co. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co. Stock Quote
Merck & Co.
$107.50 (0.64%) $0.68
Eisai Co., Ltd (ADR) Stock Quote
Eisai Co., Ltd (ADR)
$68.10 (2.50%) $1.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.